Global Leader Raises the Bar for Migraine Patients

Eli Lilly and Company  | March 19, 2020

For Lilly’s migraine team, pushing the boundaries of science started with asking bold questions.

“We listened to patients and external advisors to learn how we could reset treatment expectations. Could we push ourselves to demonstrate the medicine can help patients be migraine free?” said Jyun-Yan (Jeff) Yang, M.D., global development leader for migraine. “It allowed us to design the Phase 3 studies to raise the bar on what a migraine treatment could deliver.”

In 2019, that preventative migraine treatment – Emgality – became the U.S. leader in new-to-brand prescriptions and received FDA approval for episodic cluster headache. In 2020, Lilly launched a second new medicine, Reyvow, to stop migraine attacks when they happen – the first new class of acute migraine treatment approved by the FDA in more than two decades.

“These new medicines are bringing new optimism for people living with migraine,” Dr. Yang said.

Merle Diamond, M.D., president and managing director of the Diamond Headache Clinic in Chicago, said new classes of medication have made life better for her patients.

“Having these medications has changed my 30-year practice of headache,” said Dr. Diamond. “These are the first doors that we have been able to walk through to help our patients achieve a life without disability.”

Read more stories from the 2019 Integrated Summary Report here.